Hansa Biopharma AB (HNSA) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.253x

Based on the latest financial reports, Hansa Biopharma AB (HNSA) has a cash flow conversion efficiency ratio of 0.253x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-111.70 Million ≈ $-12.02 Million USD) by net assets (Skr-441.06 Million ≈ $-47.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hansa Biopharma AB (HNSA) net asset quality to measure how much of total assets are equity-financed.

Hansa Biopharma AB - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Hansa Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hansa Biopharma AB total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Hansa Biopharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hansa Biopharma AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ningbo Lehui International Engineering Equipment Co Ltd Class A SHG:603076	0.088x
Lanner Electronics TWO:6245	0.034x
Jiangsu Jinling Sports Equipment Co Ltd SHE:300651	0.053x
Jiangsu Tongda Power Technology Co Ltd SHE:002576	0.007x
Moso Power Supply Technology Co Ltd SHE:002660	0.069x
eDreams Odigeo SA MC:EDR	0.066x
Fastighets AB Trianon (publ) ST:TRIAN-B	0.014x
Weltrend Semiconductor Inc TW:2436	0.038x

Annual Cash Flow Conversion Efficiency for Hansa Biopharma AB (2008–2024)

The table below shows the annual cash flow conversion efficiency of Hansa Biopharma AB from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Hansa Biopharma AB.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr-589.83 Million ≈ $-63.48 Million	Skr-674.88 Million ≈ $-72.63 Million	1.144x	-74.58%
2023-12-31	Skr-167.88 Million ≈ $-18.07 Million	Skr-755.65 Million ≈ $-81.32 Million	4.501x	+639.82%
2022-12-31	Skr602.91 Million ≈ $64.88 Million	Skr-502.73 Million ≈ $-54.10 Million	-0.834x	-31.28%
2021-12-31	Skr757.57 Million ≈ $81.53 Million	Skr-481.17 Million ≈ $-51.78 Million	-0.635x	-171.79%
2020-12-31	Skr1.24 Billion ≈ $133.67 Million	Skr-290.27 Million ≈ $-31.24 Million	-0.234x	+60.71%
2019-12-31	Skr562.82 Million ≈ $60.57 Million	Skr-334.77 Million ≈ $-36.03 Million	-0.595x	-150.04%
2018-12-31	Skr859.88 Million ≈ $92.54 Million	Skr-204.56 Million ≈ $-22.01 Million	-0.238x	+0.05%
2017-12-31	Skr630.66 Million ≈ $67.87 Million	Skr-150.10 Million ≈ $-16.15 Million	-0.238x	+28.60%
2016-12-31	Skr283.69 Million ≈ $30.53 Million	Skr-94.56 Million ≈ $-10.18 Million	-0.333x	-21.99%
2015-12-31	Skr211.53 Million ≈ $22.76 Million	Skr-57.80 Million ≈ $-6.22 Million	-0.273x	+42.39%
2014-12-31	Skr49.80 Million ≈ $5.36 Million	Skr-23.62 Million ≈ $-2.54 Million	-0.474x	-45.75%
2013-12-31	Skr45.68 Million ≈ $4.92 Million	Skr-14.87 Million ≈ $-1.60 Million	-0.325x	+0.26%
2012-12-31	Skr63.24 Million ≈ $6.81 Million	Skr-20.63 Million ≈ $-2.22 Million	-0.326x	+58.28%
2011-12-31	Skr34.71 Million ≈ $3.74 Million	Skr-27.14 Million ≈ $-2.92 Million	-0.782x	-39.01%
2010-12-31	Skr32.17 Million ≈ $3.46 Million	Skr-18.09 Million ≈ $-1.95 Million	-0.563x	-1.64%
2009-12-31	Skr24.92 Million ≈ $2.68 Million	Skr-13.79 Million ≈ $-1.48 Million	-0.553x	-44.73%
2008-12-31	Skr40.73 Million ≈ $4.38 Million	Skr-15.58 Million ≈ $-1.68 Million	-0.382x	--

About Hansa Biopharma AB

ST:HNSA Sweden Biotechnology

Market Cap

$356.95 Million

Skr3.32 Billion SEK

Market Cap Rank

#13901 Global

#225 in Sweden

Share Price

Skr33.26

Change (1 day)

-3.31%

52-Week Range

Skr24.88 - Skr42.74

All Time High

Skr348.00